Gilead Sciences (NASDAQ:GILD) EVP Sells $557,809.89 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) EVP Wettan Keeley Cain sold 3,399 shares of the company’s stock in a transaction dated Friday, November 6th. The stock was sold at an average price of $164.11, for a total transaction of $557,809.89. Following the transaction, the executive vice president owned 5,360 shares of the company’s stock, valued at $879,629.60. This represents a 38.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences Stock Down 0.7%

GILD stock opened at $169.73 on Thursday. The company has a quick ratio of 1.22, a current ratio of 1.38 and a debt-to-equity ratio of 1.84. Gilead Sciences, Inc. has a fifty-two week low of $116.88 and a fifty-two week high of $176.58. The firm’s 50-day simple moving average is $154.40 and its 200 day simple moving average is $141.51. The stock has a market cap of $210.52 billion, a PE ratio of -53.71 and a beta of 0.35.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The firm had revenue of $8.30 billion for the quarter, compared to the consensus estimate of $7.81 billion. During the same period last year, the firm posted $2.47 EPS. Gilead Sciences’s quarterly revenue was up 6.8% compared to the same quarter last year. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post -0.98 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 annualized dividend and a yield of 1.9%. Gilead Sciences’s payout ratio is presently -103.80%.

Gilead Sciences News Roundup

These are some of the GILD news items that stood out recently:

• Positive Sentiment: Recent coverage also points to clinical progress in HIV and liver disease and raised full-year guidance, supporting confidence in Gilead’s outlook. Its latest reported quarter beat analyst estimates for earnings and revenue, with revenue up year over year. Gilead Sciences After Trial Wins And Raised Guidance Looks Fully Valued
• Neutral Sentiment: Valuation views are mixed after GILD’s substantial multi-year advance: one analysis sees the shares as undervalued based on cash-flow potential, while another considers them fully valued after the rally. This may make further gains more dependent on continued execution. Gilead Stock Still Looks Undervalued On Its 205% Run Gilead Looks Fully Valued
• Neutral Sentiment: Gilead partner Xilio expects to provide Gilead with an option data package for efarindodekin alfa in the first half of 2027. This is a potential pipeline catalyst, but remains several months away and is dependent on future data. Xilio Therapeutics Pipeline Update

Analysts Set New Price Targets

GILD has been the subject of several research analyst reports. JPMorgan Chase & Co. upped their price objective on shares of Gilead Sciences from $170.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Sanford C. Bernstein reissued an “outperform” rating and set a $175.00 target price on shares of Gilead Sciences in a report on Monday, November 2nd. Royal Bank Of Canada upped their target price on Gilead Sciences from $126.00 to $131.00 and gave the stock a “sector perform” rating in a research report on Friday, October 30th. Wells Fargo & Company lifted their price target on Gilead Sciences from $165.00 to $190.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Finally, Bank of America boosted their price objective on Gilead Sciences from $168.00 to $172.00 and gave the stock a “buy” rating in a research note on Tuesday, October 20th. Twenty-three analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $170.15.

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at $15,393,785,000. Legal & General Group Plc purchased a new position in shares of Gilead Sciences in the second quarter worth approximately $1,316,606,000. Deutsche Bank AG acquired a new stake in shares of Gilead Sciences during the second quarter valued at approximately $918,387,000. Jupiter Topco LLC purchased a new stake in shares of Gilead Sciences in the 2nd quarter valued at approximately $448,021,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Gilead Sciences in the 2nd quarter valued at approximately $398,905,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.